Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) saw unusually-strong trading volume on Thursday . Approximately 236,620 shares were traded during mid-day trading, a decline of 2% from the previous session’s volume of 241,794 shares.The stock last traded at $19.27 and had previously closed at $17.91.

Several research firms recently weighed in on NTLA. Jefferies Group began coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “hold” rating and a $33.00 price objective on the stock. Credit Suisse Group AG began coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective on the stock. Wedbush began coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price objective on the stock. Finally, Leerink Swann began coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective on the stock.

The company’s market cap is $695.08 million. The company has a 50 day moving average of $23.50 and a 200 day moving average of $24.58.

In other Intellia Therapeutics news, Director Carl L. Gordon bought 250,000 shares of the stock in a transaction on Wednesday, May 11th. The stock was purchased at an average price of $18.00 per share, with a total value of $4,500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Institutes For Biomed Novartis bought 277,777 shares of the stock in a transaction on Wednesday, May 11th. The shares were acquired at an average cost of $18.00 per share, with a total value of $4,999,986.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.